MX2012008790A - Antigenos de tuberculosis modificados. - Google Patents
Antigenos de tuberculosis modificados.Info
- Publication number
- MX2012008790A MX2012008790A MX2012008790A MX2012008790A MX2012008790A MX 2012008790 A MX2012008790 A MX 2012008790A MX 2012008790 A MX2012008790 A MX 2012008790A MX 2012008790 A MX2012008790 A MX 2012008790A MX 2012008790 A MX2012008790 A MX 2012008790A
- Authority
- MX
- Mexico
- Prior art keywords
- modified
- tuberculosis antigens
- tuberculosis
- antigens
- reactivation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
Proteínas Rv3616c modificadas y su uso como medicamentos, en particular para la prevención de la reactivación de tuberculosis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29871010P | 2010-01-27 | 2010-01-27 | |
PCT/EP2011/051158 WO2011092253A1 (en) | 2010-01-27 | 2011-01-27 | Modified tuberculosis antigens |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012008790A true MX2012008790A (es) | 2012-08-17 |
Family
ID=44318698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012008790A MX2012008790A (es) | 2010-01-27 | 2011-01-27 | Antigenos de tuberculosis modificados. |
Country Status (24)
Country | Link |
---|---|
US (2) | US8932600B2 (es) |
EP (1) | EP2528621B1 (es) |
JP (2) | JP6010463B2 (es) |
KR (1) | KR20120129927A (es) |
CN (1) | CN102869372B (es) |
AU (1) | AU2011209399B2 (es) |
BR (1) | BR112012018669A2 (es) |
CA (1) | CA2786969C (es) |
CO (1) | CO6650338A2 (es) |
CY (1) | CY1119518T1 (es) |
DK (1) | DK2528621T3 (es) |
EA (1) | EA201290590A1 (es) |
ES (1) | ES2614266T3 (es) |
HR (1) | HRP20161608T1 (es) |
HU (1) | HUE031184T2 (es) |
LT (1) | LT2528621T (es) |
MX (1) | MX2012008790A (es) |
MY (1) | MY156697A (es) |
PL (1) | PL2528621T3 (es) |
PT (1) | PT2528621T (es) |
SG (1) | SG182573A1 (es) |
SI (1) | SI2528621T1 (es) |
UA (1) | UA110103C2 (es) |
WO (1) | WO2011092253A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE031044T2 (en) | 2008-07-25 | 2017-06-28 | Glaxosmithkline Biologicals Sa | Polypeptides, polynucleotides and compositions for use in the treatment of latent tuberculosis |
CA2731549C (en) | 2008-07-25 | 2018-07-17 | Glaxo Group Limited | Compositions and methods for treating tuberculosis |
EP2315834B1 (en) | 2008-07-25 | 2018-06-13 | GlaxoSmithKline Biologicals S.A. | The tuberculosis rv2386c protein, compositions and uses thereof |
BR112012018669A2 (pt) * | 2010-01-27 | 2017-09-05 | Glaxosmithkline Biologicals Sa | Proteína rv3616c modificada, uso de uma proteína rv3616c modificada, polinucleotídeo, uso de um polinucleotídeo, composição farmacêutica, composição imunogênica, proteína de fusão, e, polipeptídeo. |
GB201116248D0 (en) | 2011-09-20 | 2011-11-02 | Glaxosmithkline Biolog Sa | Liposome production using isopropanol |
WO2013123579A1 (en) * | 2012-02-24 | 2013-08-29 | Mcmaster University | Adenovirus-based tuberculosis vaccine and its use |
CN103467582A (zh) * | 2012-06-08 | 2013-12-25 | 同济大学 | 结核杆菌重要抗原的高通量筛选及其在结核病诊断中的应用 |
ES2925950T3 (es) | 2013-06-25 | 2022-10-20 | Int Aids Vaccine Initiative Inc | Composiciones para la tuberculosis y procedimientos de uso de las mismas |
WO2015148960A1 (en) * | 2014-03-28 | 2015-10-01 | The Board Of Regents Of The University Of Oklahoma | Compositions comprising soluble hla/m. tuberculosis-specific ligand complexes and methods of production and use thereof |
GB201405921D0 (en) * | 2014-04-02 | 2014-05-14 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
GB201513176D0 (en) * | 2015-07-27 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
CN105675863B (zh) * | 2016-02-17 | 2017-10-20 | 遵义医学院附属医院 | 一组耐多药结核病诊断标志物及其用途 |
CA3027995A1 (en) | 2016-06-16 | 2017-12-21 | Aeras | Tuberculosis compositions and methods of treating or preventing tuberculosis |
CN106546737A (zh) * | 2016-10-24 | 2017-03-29 | 广州迪澳医疗科技有限公司 | 一种体外检测活动性结核的方法 |
GB201618432D0 (en) * | 2016-11-01 | 2016-12-14 | Matn Scient Ltd | Detection and treatment of demyelinating diseases |
US10695424B2 (en) | 2016-12-07 | 2020-06-30 | Glaxosmithkline Biologicals S.A. | Method of making a liposome composition |
GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
GB201707700D0 (en) | 2017-05-12 | 2017-06-28 | Glaxosmithkline Biologicals Sa | Dried composition |
IE20190084A3 (en) | 2017-05-30 | 2023-07-19 | Glaxosmithkline Biologicals Sa | Novel methods for manufacturing an adjuvant |
EP3717001A1 (en) | 2017-12-01 | 2020-10-07 | GlaxoSmithKline Biologicals S.A. | Saponin purification |
CN109966170B (zh) * | 2018-02-13 | 2022-04-15 | 深圳高尚科美生物科技有限公司 | 包含生物大分子的柔性脂质体化妆品及其制备方法 |
CA3142300A1 (en) | 2019-06-05 | 2020-12-10 | Glaxosmithkline Biologicals Sa | Saponin purification |
CN116669707A (zh) * | 2020-08-05 | 2023-08-29 | 杜兰教育基金管理委员会 | 体液样品中结核的检测方法 |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1786412A (en) * | 1929-11-20 | 1930-12-23 | American Telephone & Telegraph | Shielding arrangement |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US5811128A (en) | 1986-10-24 | 1998-09-22 | Southern Research Institute | Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
WO1989001973A2 (en) | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
EP1001032A3 (en) | 1989-08-18 | 2005-02-23 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
AU7258491A (en) * | 1990-02-09 | 1991-09-03 | E.I. Du Pont De Nemours And Company | Htlv envelope antigenic segment |
US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
EP0598816B1 (en) | 1991-08-15 | 1999-06-23 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Osp a proteins of borrelia burgdorferi subgroups, encoding genes and vaccines |
US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
EP0641192B1 (en) | 1992-05-18 | 1997-07-23 | Minnesota Mining And Manufacturing Company | Transmucosal drug delivery device |
US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
US5928647A (en) | 1993-01-11 | 1999-07-27 | Dana-Farber Cancer Institute | Inducing cytotoxic T lymphocyte responses |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US5551622A (en) | 1994-07-13 | 1996-09-03 | Yoon; Inbae | Surgical stapler |
AT402926B (de) | 1994-12-05 | 1997-09-25 | Hafslund Nycomed Pharma | Heterocyclische amide, verfahren zu ihrer herstellung und verwendung |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
EP0832282A1 (en) | 1995-06-02 | 1998-04-01 | Incyte Pharmaceuticals, Inc. | IMPROVED METHOD FOR OBTAINING FULL-LENGTH cDNA SEQUENCES |
US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
US6290969B1 (en) | 1995-09-01 | 2001-09-18 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
US6458366B1 (en) | 1995-09-01 | 2002-10-01 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
CN1554664A (zh) | 1995-09-01 | 2004-12-15 | 用于结核病诊断的化合物和方法 | |
ATE337399T1 (de) | 1995-09-01 | 2006-09-15 | Corixa Corp | Zusammensetzungen zur immuntherapie und diagnose von tuberculosis |
US6592877B1 (en) | 1995-09-01 | 2003-07-15 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
US6338852B1 (en) | 1995-09-01 | 2002-01-15 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
EP0871747A1 (en) | 1996-01-02 | 1998-10-21 | Chiron Viagene, Inc. | Immunostimulation mediated by gene-modified dendritic cells |
CZ126699A3 (cs) | 1996-10-11 | 1999-09-15 | Corixa Corporation | Polypeptid obsahující antigenní část rozpustného antigenu M. tuberculosis nebo variantu uvedeného antigenu, molekula DNA kódující tento polypeptid, expresivní vektor, hostitelská buňka, způsoby diagnostiky infekce M. tuberculosis a diagnostické kity |
US6627198B2 (en) | 1997-03-13 | 2003-09-30 | Corixa Corporation | Fusion proteins of Mycobacterium tuberculosis antigens and their uses |
US6350456B1 (en) | 1997-03-13 | 2002-02-26 | Corixa Corporation | Compositions and methods for the prevention and treatment of M. tuberculosis infection |
US6544522B1 (en) | 1998-12-30 | 2003-04-08 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis antigens and their uses |
US6555653B2 (en) | 1997-05-20 | 2003-04-29 | Corixa Corporation | Compounds for diagnosis of tuberculosis and methods for their use |
US6613881B1 (en) | 1997-05-20 | 2003-09-02 | Corixa Corporation | Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use |
SI1659179T1 (sl) | 1998-02-05 | 2011-10-28 | Glaxosmithkline Biolog Sa | S tumorjem povezani antigenski derivati iz MAGE druĹľine in zaporedja nukleinskih kislin, ki jih kodirajo, uporabni za pripravo fuzijskih proteinov in sestavkov za cepljenje |
CZ302870B6 (cs) | 1998-04-07 | 2011-12-28 | Corixa Corporation | Polynukleotid, polypeptid, farmaceutický prostredek, vakcínový prostredek a jejich použití k lécbe a prevenci infekce tuberkulózou |
TR200101055T2 (tr) | 1998-10-16 | 2001-09-21 | Smithkline Beecham Biologicals S.A. | Adjuvan sistemler ve aşılar |
EP1229931A4 (en) * | 1999-10-07 | 2003-05-28 | Corixa Corp | FUSION PROTEINS FROM MYCOBACTERIUM TUBERCULOSIS |
WO2001062893A2 (en) * | 2000-02-25 | 2001-08-30 | Corixa Corporation | Compounds and methods for diagnosis and immunotherapy of tuberculosis |
SI1542732T1 (sl) | 2000-06-20 | 2010-01-29 | Corixa Corp Csc The United Sta | Fuzijski proteini Mycobacterium tuberculosis |
CN1277843C (zh) | 2001-02-22 | 2006-10-04 | 巴斯德研究院 | 分枝杆菌比较基因组学作为鉴定分枝杆菌病的诊断、预防或治疗靶的工具 |
US20030175294A1 (en) * | 2001-03-13 | 2003-09-18 | Corixa Corporation | Heterologous fusion protein constructs comprising a Leishmania antigen |
US7300998B2 (en) | 2002-02-14 | 2007-11-27 | Mitsui Chemicals, Inc. | Polyester resin and catalyst for polyester production, process for producing polyester resin with the catalyst, polyester resin obtained with the catalyst, and hollow molded container comprising the polyester resins |
US7026465B2 (en) | 2002-02-15 | 2006-04-11 | Corixa Corporation | Fusion proteins of Mycobacterium tuberculosis |
JP2006512047A (ja) * | 2002-06-11 | 2006-04-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
US7205259B2 (en) | 2002-07-26 | 2007-04-17 | Kimberly-Clark Worldwide, Inc. | Absorbent binder desiccant composition and articles incorporating it |
GB0323965D0 (en) * | 2003-10-13 | 2003-11-19 | Glaxosmithkline Biolog Sa | Immunogenic compositions |
EP1846931A1 (en) | 2005-01-19 | 2007-10-24 | Panduit Corporation | Communication channels with suppression cores |
PL1877426T3 (pl) | 2005-04-29 | 2012-10-31 | Glaxosmithkline Biologicals Sa | Sposób profilaktyki lub leczenia zakażenia M. tuberculosis |
WO2006117538A2 (en) * | 2005-04-29 | 2006-11-09 | Fusion Antibodies Limited | Assays for diagnosis of tuberculosis and uses thereof |
US9017999B2 (en) | 2005-05-03 | 2015-04-28 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Importation of mitochondrial protein by an enhanced allotopic approach |
JP4468858B2 (ja) | 2005-06-01 | 2010-05-26 | オリンパスイメージング株式会社 | データ符号化装置、データ符号化方法、プログラム |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
US7296798B2 (en) | 2006-01-31 | 2007-11-20 | Matt Overfield | Gameboard, games played on board and methods of play requiring strategy and luck |
WO2008007942A1 (en) * | 2006-07-10 | 2008-01-17 | Het Nederlands Kanker Instituut | Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof |
CN101522218B (zh) | 2006-10-12 | 2012-09-26 | 葛兰素史密丝克莱恩生物有限公司 | 包含水包油乳液佐剂的疫苗 |
CA2668100C (en) * | 2006-11-01 | 2014-12-23 | Immport Therapeutics, Inc. | Compositions and methods for immunodominant antigens |
GB0622282D0 (en) * | 2006-11-08 | 2006-12-20 | Novartis Ag | Quality control methods |
EA021391B1 (ru) * | 2007-03-02 | 2015-06-30 | Глаксосмитклайн Байолоджикалс С.А. | Способ индукции иммунного ответа, вакцинная композиция, ее применение и набор |
GB0716070D0 (en) * | 2007-08-17 | 2007-09-26 | Fusion Antibodies Ltd | Diagnostic method and kit |
US7670609B2 (en) * | 2007-11-27 | 2010-03-02 | Aeras Global Tb Vaccine Foundation | Recombinant BCG tuberculosis vaccine designed to elicit immune responses to Mycobacterium tuberculosis in all physiological stages of infection and disease |
FR2933552B1 (fr) | 2008-07-04 | 2014-10-10 | Centre Nat Rech Scient | Circuit d'amplification d'un signal representant une variation de resistance d'une resistance variable et capteur correspondant |
HUE031044T2 (en) * | 2008-07-25 | 2017-06-28 | Glaxosmithkline Biologicals Sa | Polypeptides, polynucleotides and compositions for use in the treatment of latent tuberculosis |
EP2421557B1 (en) | 2009-04-24 | 2018-12-05 | Statens Serum Institut | A tuberculosis tb vaccine to prevent reactivation |
EP2457018A4 (en) | 2009-07-21 | 2014-10-15 | Cooper Technologies Co | CONNECTING A LIGHT EMITTING DIODE MODULE (LED) TO A THERMAL DISSIPATING ASSEMBLY, LIGHT REFLECTOR, AND ELECTRIC CIRCUITS |
BR112012018669A2 (pt) * | 2010-01-27 | 2017-09-05 | Glaxosmithkline Biologicals Sa | Proteína rv3616c modificada, uso de uma proteína rv3616c modificada, polinucleotídeo, uso de um polinucleotídeo, composição farmacêutica, composição imunogênica, proteína de fusão, e, polipeptídeo. |
US9119754B2 (en) | 2011-10-08 | 2015-09-01 | Michael Dennis | Mattress overlay system with positionally adjustable, lateral ramp-wedge bolster structure |
US9051890B2 (en) | 2013-10-28 | 2015-06-09 | Ford Global Technologies, Llc | Method for estimating charge air cooler condensation storage with an intake oxygen sensor |
US9903268B2 (en) | 2015-04-02 | 2018-02-27 | Ford Global Technologies, Llc | Internal combustion engine with two-stage supercharging capability and with exhaust-gas aftertreatment arrangement, and method for operating an internal combustion engine |
US9810514B2 (en) | 2015-09-08 | 2017-11-07 | Deufol Sunman Inc. | Ammunition carrier consumer package |
-
2011
- 2011-01-27 BR BR112012018669A patent/BR112012018669A2/pt not_active Application Discontinuation
- 2011-01-27 CN CN201180014803.7A patent/CN102869372B/zh active Active
- 2011-01-27 JP JP2012550445A patent/JP6010463B2/ja active Active
- 2011-01-27 ES ES11700859.9T patent/ES2614266T3/es active Active
- 2011-01-27 EP EP11700859.9A patent/EP2528621B1/en active Active
- 2011-01-27 PL PL11700859T patent/PL2528621T3/pl unknown
- 2011-01-27 AU AU2011209399A patent/AU2011209399B2/en not_active Ceased
- 2011-01-27 MX MX2012008790A patent/MX2012008790A/es active IP Right Grant
- 2011-01-27 SI SI201131036A patent/SI2528621T1/sl unknown
- 2011-01-27 WO PCT/EP2011/051158 patent/WO2011092253A1/en active Application Filing
- 2011-01-27 DK DK11700859.9T patent/DK2528621T3/da active
- 2011-01-27 PT PT117008599T patent/PT2528621T/pt unknown
- 2011-01-27 KR KR1020127022290A patent/KR20120129927A/ko not_active Application Discontinuation
- 2011-01-27 LT LTEP11700859.9T patent/LT2528621T/lt unknown
- 2011-01-27 CA CA2786969A patent/CA2786969C/en active Active
- 2011-01-27 UA UAA201209252A patent/UA110103C2/uk unknown
- 2011-01-27 HU HUE11700859A patent/HUE031184T2/en unknown
- 2011-01-27 US US13/574,816 patent/US8932600B2/en active Active
- 2011-01-27 SG SG2012052767A patent/SG182573A1/en unknown
- 2011-01-27 MY MYPI2012003347A patent/MY156697A/en unknown
- 2011-01-27 EA EA201290590A patent/EA201290590A1/ru unknown
-
2012
- 2012-07-25 CO CO12125075A patent/CO6650338A2/es not_active Application Discontinuation
-
2014
- 2014-12-02 US US14/557,929 patent/US9200044B2/en active Active
-
2016
- 2016-03-04 JP JP2016042444A patent/JP6503309B2/ja active Active
- 2016-12-01 HR HRP20161608TT patent/HRP20161608T1/hr unknown
- 2016-12-06 CY CY20161101254T patent/CY1119518T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
JP6010463B2 (ja) | 2016-10-19 |
JP2013517783A (ja) | 2013-05-20 |
LT2528621T (lt) | 2016-12-12 |
DK2528621T3 (da) | 2017-01-02 |
US9200044B2 (en) | 2015-12-01 |
HRP20161608T1 (hr) | 2017-01-13 |
US20150093414A1 (en) | 2015-04-02 |
UA110103C2 (uk) | 2015-11-25 |
PT2528621T (pt) | 2016-12-20 |
EA201290590A1 (ru) | 2013-03-29 |
US8932600B2 (en) | 2015-01-13 |
US20120294882A1 (en) | 2012-11-22 |
SG182573A1 (en) | 2012-08-30 |
MY156697A (en) | 2016-03-15 |
HUE031184T2 (en) | 2017-06-28 |
CA2786969A1 (en) | 2011-08-04 |
PL2528621T3 (pl) | 2017-07-31 |
CN102869372B (zh) | 2016-01-20 |
EP2528621B1 (en) | 2016-09-21 |
JP6503309B2 (ja) | 2019-04-17 |
WO2011092253A1 (en) | 2011-08-04 |
SI2528621T1 (sl) | 2017-01-31 |
CY1119518T1 (el) | 2018-03-07 |
JP2016166193A (ja) | 2016-09-15 |
EP2528621A1 (en) | 2012-12-05 |
AU2011209399A1 (en) | 2012-08-23 |
CO6650338A2 (es) | 2013-04-15 |
CA2786969C (en) | 2018-07-24 |
BR112012018669A2 (pt) | 2017-09-05 |
CN102869372A (zh) | 2013-01-09 |
KR20120129927A (ko) | 2012-11-28 |
AU2011209399B2 (en) | 2014-04-10 |
ES2614266T3 (es) | 2017-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY156697A (en) | Modified tuberculosis antigens | |
PH12017501417A1 (en) | Anti-fap antibodies and methods of use | |
IL252154A0 (en) | Antibodies against dr5, preparations containing them and their uses | |
TN2012000414A1 (en) | Forms of rifaximin and uses thereof | |
MX2013008390A (es) | Preparacion de estructuras de metal-triazolato. | |
PH12014502601A1 (en) | ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | |
GB201106750D0 (en) | Novel compounds | |
MX342240B (es) | Anticuerpos anti-fgfr4 y metodos de uso. | |
EP4303236A3 (en) | Cytotoxicity-inducing therapeutic agent | |
MX2013015311A (es) | Polipeptidos de enlace de pcsk9 y metodos de uso. | |
MX2015001601A (es) | Metodos de tratamiento de una tauopatia. | |
MX2015001083A (es) | Polipeptidos de factor x modificados y usos de los mismos. | |
MX2014004022A (es) | Anticuerpos anti-htra1 y metodos de uso. | |
MX340555B (es) | Anticuerpos contra il-18r1 y usos de los mismos. | |
MX347734B (es) | Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas. | |
TW201144301A (en) | Processes for preparing linezolid | |
MX368288B (es) | Una combinación de anticuerpos anti-cd38 y melfalán para usarse en el tratamiento de mieloma múltiple. | |
EP2571982A4 (en) | ANTIGEN-SPECIFIC TREGS AND CORRESPONDING COMPOSITIONS, METHODS AND SYSTEMS | |
MX2013002784A (es) | Heteroarilos fusionados y sus usos. | |
MX2012011829A (es) | Anticuerpos de anti-poliubiquitina y metodos de uso. | |
MX357675B (es) | Anticuerpos anti-jagged y métodos de uso. | |
EP2569327A4 (en) | EIF4E BINDING PEPTIDES | |
EP4233915A3 (en) | Modified release formulations of viloxazine | |
UA73620U (uk) | Засіб для зупинки кровотечі "желпластан" | |
UA70698U (ru) | Применение 2-метил-3-фениламинометилхинолин-4-она как противогипоксического, актопротекторного и антиалкогольного средства |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |